恩華藥業(002262.SZ):上半年淨利潤5.45億元,同比增長21.72%
格隆匯7月30日丨恩華藥業(002262.SZ)公佈2023年半年度報吿,報吿期營業收入24億元,同比增長19.95%。歸屬於上市公司股東的淨利潤5.45億元,同比增長21.72%。歸屬於上市公司股東的扣除非經常性損益的淨利潤5.45億元,同比增長21.26%。基本每股收益0.54元。
報吿期內,公司主要的業績驅動因素體現在以下方面:1、根據臨牀需求及痛點制定重點產品品牌策略,建立產品的差異化競爭優勢,使充分競爭的品種保持增長。2、高度重視市場準入、學術推廣及市場醫學服務支持等工作,使公司近年獲批的麻醉系列產品實現了快速增長。3、通過將麻醉和精神線產品的業務下沉,深度挖掘縣域基層與民營醫院市場,保證了非集採產品的較快增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.